Literature DB >> 19515777

Human VAP-C negatively regulates hepatitis C virus propagation.

Hiroshi Kukihara1, Kohji Moriishi, Shuhei Taguwa, Hideki Tani, Takayuki Abe, Yoshio Mori, Tetsuro Suzuki, Takasuke Fukuhara, Akinobu Taketomi, Yoshihiko Maehara, Yoshiharu Matsuura.   

Abstract

Human vesicle-associated membrane protein-associated protein (VAP) subtype A (VAP-A) and subtype B (VAP-B) are involved in the regulation of membrane trafficking, lipid transport and metabolism, and the unfolded protein response. VAP-A and VAP-B consist of the major sperm protein (MSP) domain, the coiled-coil motif, and the C-terminal transmembrane anchor and form homo- and heterodimers through the transmembrane domain. VAP-A and VAP-B interact with NS5B and NS5A of hepatitis C virus (HCV) through the MSP domain and the coiled-coil motif, respectively, and participate in the replication of HCV. VAP-C is a splicing variant of VAP-B consisting of the N-terminal half of the MSP domain of VAP-B followed by the subtype-specific frameshift sequences, and its biological function has not been well characterized. In this study, we have examined the biological functions of VAP-C in the propagation of HCV. VAP-C interacted with NS5B but not with VAP-A, VAP-B, or NS5A in immunoprecipitation analyses, and the expression of VAP-C inhibited the interaction of NS5B with VAP-A or VAP-B. Overexpression of VAP-C impaired the RNA replication of the HCV replicon and the propagation of the HCV JFH1 strain, whereas overexpression of VAP-A and VAP-B enhanced the replication. Furthermore, the expression of VAP-C was observed in various tissues, whereas it was barely detected in the liver. These results suggest that VAP-C acts as a negative regulator of HCV propagation and that the expression of VAP-C may participate in the determination of tissue tropism of HCV propagation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515777      PMCID: PMC2715746          DOI: 10.1128/JVI.00889-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Structural basis of FFAT motif-mediated ER targeting.

Authors:  Stephen E Kaiser; Jason H Brickner; Amy R Reilein; Tim D Fenn; Peter Walter; Axel T Brunger
Journal:  Structure       Date:  2005-07       Impact factor: 5.006

2.  Different anti-HCV profiles of statins and their potential for combination therapy with interferon.

Authors:  Masanori Ikeda; Ken-ichi Abe; Masashi Yamada; Hiromichi Dansako; Kazuhito Naka; Nobuyuki Kato
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

Review 3.  Course and outcome of hepatitis C.

Authors:  Jay H Hoofnagle
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

4.  Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice.

Authors:  Shin-ichiro Nakagawa; Takuya Umehara; Chiho Matsuda; Shusuke Kuge; Masayuki Sudoh; Michinori Kohara
Journal:  Biochem Biophys Res Commun       Date:  2006-12-22       Impact factor: 3.575

5.  Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex.

Authors:  Denise Egger; Benno Wölk; Rainer Gosert; Leonardo Bianchi; Hubert E Blum; Darius Moradpour; Kurt Bienz
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein.

Authors:  Kohji Moriishi; Tamaki Okabayashi; Kousuke Nakai; Kyoji Moriya; Kazuhiko Koike; Shigeo Murata; Tomoki Chiba; Keiji Tanaka; Ryosuke Suzuki; Tetsuro Suzuki; Tatsuo Miyamura; Yoshiharu Matsuura
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets.

Authors:  John McLauchlan; Marius K Lemberg; Graham Hope; Bruno Martoglio
Journal:  EMBO J       Date:  2002-08-01       Impact factor: 11.598

8.  Molecular cloning and characterization of mammalian homologues of vesicle-associated membrane protein-associated (VAMP-associated) proteins.

Authors:  Y Nishimura; M Hayashi; H Inada; T Tanaka
Journal:  Biochem Biophys Res Commun       Date:  1999-01-08       Impact factor: 3.575

9.  Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase.

Authors:  Timothy L Tellinghuisen; Joseph Marcotrigiano; Charles M Rice
Journal:  Nature       Date:  2005-05-19       Impact factor: 49.962

10.  Human butyrate-induced transcript 1 interacts with hepatitis C virus NS5A and regulates viral replication.

Authors:  Shuhei Taguwa; Toru Okamoto; Takayuki Abe; Yoshio Mori; Tetsuro Suzuki; Kohji Moriishi; Yoshiharu Matsuura
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

View more
  11 in total

Review 1.  VAP Proteins - From Organelle Tethers to Pathogenic Host Interactors and Their Role in Neuronal Disease.

Authors:  Suzan Kors; Joseph L Costello; Michael Schrader
Journal:  Front Cell Dev Biol       Date:  2022-06-08

2.  VAMP-associated Proteins (VAP) as Receptors That Couple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Proteostasis with Lipid Homeostasis.

Authors:  Wayne L Ernst; Kuntala Shome; Christine C Wu; Xiaoyan Gong; Raymond A Frizzell; Meir Aridor
Journal:  J Biol Chem       Date:  2016-01-06       Impact factor: 5.157

3.  Prolactin Regulatory Element Binding Protein Is Involved in Hepatitis C Virus Replication by Interaction with NS4B.

Authors:  Lingbao Kong; Akira Fujimoto; Mariko Nakamura; Haruyo Aoyagi; Mami Matsuda; Koichi Watashi; Ryosuke Suzuki; Minetaro Arita; Satoshi Yamagoe; Naoshi Dohmae; Takehiro Suzuki; Yuriko Sakamaki; Shizuko Ichinose; Tetsuro Suzuki; Takaji Wakita; Hideki Aizaki
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

Review 4.  The unfolded protein response in fatty liver disease.

Authors:  Anne Henkel; Richard M Green
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

Review 5.  Sperm and oocyte communication mechanisms controlling C. elegans fertility.

Authors:  Sung Min Han; Pauline A Cottee; Michael A Miller
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

6.  Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules.

Authors:  Xiaoyu Wen; Takayuki Abe; Hiroshi Kukihara; Shuhei Taguwa; Yoshio Mori; Hideki Tani; Nobuyuki Kato; Tetsuro Suzuki; Masashi Tatsumi; Kohji Moriishi; Yoshiharu Matsuura
Journal:  PLoS One       Date:  2011-01-06       Impact factor: 3.240

7.  Completion of hepatitis C virus replication cycle in heterokaryons excludes dominant restrictions in human non-liver and mouse liver cell lines.

Authors:  Anne Frentzen; Kathrin Hüging; Julia Bitzegeio; Martina Friesland; Sibylle Haid; Juliane Gentzsch; Markus Hoffmann; Dirk Lindemann; Gert Zimmer; Florian Zielecki; Friedemann Weber; Eike Steinmann; Thomas Pietschmann
Journal:  PLoS Pathog       Date:  2011-04-28       Impact factor: 6.823

8.  Exploitation of lipid components by viral and host proteins for hepatitis C virus infection.

Authors:  Kohji Moriishi; Yashiharu Matsuura
Journal:  Front Microbiol       Date:  2012-02-14       Impact factor: 5.640

9.  VAPC, an human endogenous inhibitor for hepatitis C virus (HCV) infection, is intrinsically unstructured but forms a "fuzzy complex" with HCV NS5B.

Authors:  Shaveta Goyal; Garvita Gupta; Haina Qin; Megha Haridas Upadya; Yee Joo Tan; Vincent T K Chow; Jianxing Song
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

Review 10.  Towards a small animal model for hepatitis C.

Authors:  Alexander Ploss; Charles M Rice
Journal:  EMBO Rep       Date:  2009-10-16       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.